Drug Discovery · Cambridge, MA · Founded 2019 · In IPO Registration
Developer of prophylactic therapeutics designed for bleeding and thrombosis disorders. Hemab Therapeutics Holdings is based in Cambridge, MA and was founded in 2019. It is valued at about $387 million as of Oct 2026, set by institutional fund marks. It has raised $355 million across 2 recorded rounds; the latest was a $157 million Series C in Oct 2025.
PMV mark · valuation
$386.9M
Oct 2026
Priced at
its later-stage round
Oct 2025
Total raised
$355.1M
Last round
Later Stage VC (Series C)
Oct 2025
No prints on record
No secondary trades in Hemab Therapeutics Holdings shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Where Hemab Therapeutics Holdings prices come from
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Hemab Therapeutics Holdings stock.
